home · filing · 0000950170-24-125940
8-K filed November 13, 2024, 6:59 PM ET
ticker LXEO
CIK 0001907108
other material
confidence high
sentiment positive
materiality 0.80
Lexeo reaches FDA alignment on accelerated approval for LX2006; Q3 net loss $29.5M, cash $157M
Lexeo Therapeutics, Inc.
2024-Q3 EPS reported
-$2.31
FDA agreed on co-primary registrational endpoints (LVMI reduction and frataxin expression) for LX2006 accelerated approval.
Received RMAT designation for LX2006; completed enrollment in SUNRISE-FA Phase 1/2 (16 patients dosed to date).
LX2020 PKP2-ACM cohort 1 enrollment completed; initial safety/biodistribution data expected late Q1/Q2 2025.
Q3 net loss $29.5M ($0.89 per share) vs $20.1M year-ago; R&D $23.4M, G&A $8.1M.
Cash $157M expected into 2027; Tolga Tanguler (Alnylam exec) appointed to board.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-11-11
Filed November 13, 2024, 6:59 PM ET
On November 11, 2024 (the “ Appointment Date ”), Tolga Tanguler was appointed to the board of directors of the Company (the “ Board ”).
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Tolga Tanguler was appointed as director at Lexeo Therapeutics, Inc..
Action appointed
Role director
Exact text from the filing
On November 11, 2024 (the “ Appointment Date ”), Tolga Tanguler was appointed to the board of directors of the Company (the “ Board ”).
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-24-125940
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.